RLS-1496 topical cream for actinic keratosis
undiscloseddrug program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether topical RLS-1496 can safely clear or reduce actinic keratoses by targeting pathologic senescent cells.
Once-daily topical RLS-1496 cream applied for 28 days to actinic keratosis lesions and adjacent skin on one forearm, with the untreated contralateral forearm used as control; lesion counts, clinic visits, and skin biopsies are used for assessment.
Clinical trial evaluating safety, tolerability, and actinic keratosis lesion reduction is listed in public records.
Senotherapeutics biomarker translation program
exploratorybiomarker · low · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Advance translation of senotherapeutics through biomarker development and coordination.
Biomarker consortium work described in a Nature Aging publication title.
2026 Nature Aging publication titled "Advancing senescence translation through the Senotherapeutics Biomarker Consortium."
Neuronal senescence in dorsal root ganglia research program
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate neuronal senescence in dorsal root ganglia as a targetable mechanism for sensory dysfunction and chronic pain, especially in aging populations.
Mouse aging and peripheral nerve injury studies, senescence-marker profiling, IL6-related excitability assessment, senescent-cell elimination experiments, nociceptive behavior testing, and human post-mortem dorsal root ganglia analysis.
2025 Nature Neuroscience publication reported senescent neurons in mouse and human dorsal root ganglia and behavioral improvement after senescent-cell elimination in nerve-injured mice.
Senescent DRG neurons increased with age and injury, showed pro-inflammatory and nociceptor-like features, and eliminating senescent cells improved nociceptive behaviors in nerve-injured mice.
ALEMBIC drug discovery platform
exploratoryplatform · medium
Discover medicines intended to keep people biologically young by targeting pathologic cells that drive aging and disease.
Company-described drug discovery platform for identifying medicines against aging-related pathologic cells.
Described by Rubedo as its drug discovery platform.
RLS-1496
undiscloseddrug program · high
Develop a medicine targeting pathologic aging cells and surrounding tissues that drive aging and chronic disease.
First-in-class GPX4 modulator described as Rubedo's lead candidate.
Listed by Rubedo as its lead candidate on the company pipeline.
